Table 1.
Meningococcal conjugate and recombinant protein vaccines used globally
| Vaccine | Type | Meningococcal serogroups (other antigens) | European indication, age* |
|---|---|---|---|
| Monovalent | |||
| MenAfricVac (PsA-TT)6,7 | TT conjugate | A | Not licensed in Europe |
| Menjugate (MenC-CRM197 adsorbed to aluminum hydroxide)8 | CRM197 conjugate | C | ≥2 mo |
| Meningitec (MenC-CRM197 adsorbed to aluminum phosphate)9,10 | CRM197 conjugate | C | Discontinued in Europe |
| NeisVac-C (MenC-TT)11 | TT conjugate | C | ≥2 mo |
| Bexsero (MenB-4C)12 | Recombinant protein | B | ≥2 mo |
| Trumenba (MenB-FHbp)13 | Recombinant protein | B | ≥10 y |
| Combination | |||
| MenHibrix (HibMenCY-TT)14 | TT conjugate | C, Y (Hib) | Not licensed in Europe |
| Menitorix (Hib-MenC-TT)15 | TT conjugate | C (Hib) | ≥2 mo |
| Quadrivalent | |||
| Nimenrix (MenACWY-TT)16 | TT conjugate | A, C, W, Y | ≥6 wk |
| Menveo (MenACWY-CRM197)17 | CRM197 conjugate | A, C, W, Y | ≥2 y |
| Menactra (MenACWY-D)18 | D conjugate | A, C, W, Y | Not licensed in Europe |
| MenQuadfi (MenACYW-TT)19 | TT conjugate | A, C, W, Y | Not licensed in Europe |
CRM197, diphtheria protein cross-reactive material 197; D, diphtheria toxin; Hib, Haemophilus influenzae type b; TT, tetanus toxoid.
*For currently available vaccines.